Business

Medtronic Announces Closing of Public Offering of €1.5 Billion of Senior Notes

Medtronic plc (the "Company") (NYSE: MDT) announced today that its wholly-owned indirect subsidiary, Medtronic, Inc., has closed a registered public offering (the "Offering") of €750,000,000 principal amount of 2.950% senior notes due 2030 and €750,000,000 principal amount of 4.200% senior notes due 2045 (collectively, the "Notes"). All of Medtronic, Inc.'s obligations under the Notes are fully and unconditionally guaranteed by the Company and Medtronic Global Holdings S.C.A. ("Medtronic Luxco")

articleMedtronic Plc.September 29, 20253/company/medtronic-plc/news/medtronic-announces-closing-of-public-offering-of-euro15-billion-of-senior-notes
Medtronic Announces Closing of Public Offering of €1.5 Billion of Senior Notes

About this update from Medtronic Plc.

[{"type":"text","content":"GALWAY, Ireland, Sept. 29, 2025 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE: MDT) announced today that its wholly-owned indirect subsidiary, Medtronic, Inc., has closed a registered public offering (the "Offering") of €750,000,000 principal amount of 2.950% senior notes due 2030 and €750,000,000 principal amount of 4.200% senior notes due 2045 (collectively, the "Notes"). All of Medtronic, Inc.'s obligations under the Notes are fully and unconditionally guaranteed by the Company and Medtronic Global Holdings S.C.A. ("Medtronic Luxco"), a wholly-owned subsidiary of the Company and the indirect parent of Medtronic, Inc., on a senior unsecured basis.","length":707,"tagName":"p"},{"type":"text","content":"The net proceeds from the Offering are approximately €1.49 billion, after deducting underwriting discounts and estimated expenses related to the Offering payable by Medtronic, Inc. The net proceeds of the Offering are expected to be used to repay Medtronic Luxco's 0.000% Senior Notes due 2025 and Medtronic Luxco's 2.625% Senior Notes due 2025.","length":358,"tagName":"p"},{"type":"text","content":"Deutsche Bank AG, London Branch and Goldman Sachs & Co. LLC were the joint book-running managers for the Offering. The Offering was made by means of a prospectus dated March 3, 2023 and prospectus supplement (together, the "Prospectus"), copies of which may be obtained for free by visiting EDGAR on the U.S. Securities and Exchange Commission website at www.sec.gov. Alternatively, copies of the Prospectus may be obtained by contacting Deutsche Bank AG, London Branch, toll-free at +1 800-503-4611 and Goldman Sachs & Co. LLC, toll-free at +1 866-471-2526.","length":576,"tagName":"p"},{"type":"text","content":" About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical to...

More updates from Medtronic Plc.

Medtronicnet proceedsLondon BranchDeutsche Bank AG